Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non‐tumorigenic and tumorigenic cells in vitro

No abstract is available for this paper.

• Publication year

  1993

• Venue

  International Journal of Cancer

• Publication date

  1993-03-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.2910530526PMID 8449612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumors of the Female Reproductive Organs

  1994cited by this paper
• Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry.

  1992cited by this paper
• Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells.

  1992cited by this paper
• Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins.

  1992cited by this paper
• Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.

  1992cited by this paper
• Induction of apoptosis in fibroblasts by c-myc protein.

  1992cited by this paper
• Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

  1992cited by this paper
• Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells.

  1991cited by this paper
• Topoisomerase Inhibitors Have Potent Differentiation‐inducing Activity for Human and Mouse Myeloid Leukemia Cells

  1991cited by this paper
• The S-phase cytotoxicity of camptothecin.

  1991cited by this paper
• The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.

  1991cited by this paper
• Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes

  1991cited by this paper
• Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.

  1991cited by this paper
• Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the her‐2/neu oncogene

  1991cited by this paper
• Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

  1991cited by this paper
• A Reversed-Phase HPLC Method For Determining Camptothecin In Plasma With Specificity For the Intact Lactone Form of the Drug

  1991cited by this paper
• Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

  1991cited by this paper
• Participation of p53 protein in the cellular response to DNA damage.

  1991cited by this paper
• An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

  1990cited by this paper
• Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription.

  1990cited by this paper
• Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells.

  1990cited by this paper
• Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.

  1990cited by this paper
• Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

  1990cited by this paper
• DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

  1989cited by this paper
• Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

  1988cited by this paper
• Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines.

  1988cited by this paper
• Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.

  1988cited by this paper
• Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

  1987cited by this paper
• Expression of the human apolipoprotein AI gene fused to the E. coli gene for β‐galactosidase

  1986cited by this paper
• Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.

  1986cited by this paper
• Flow cytometry and biochemical analysis of DNA degradation characteristic of two types of cell death

  1986cited by this paper
• The nude mouse in cancer research.

  1985cited by this paper
• Correlation between response to chemotherapy of human tumors in patients and in nude mice

  1983cited by this paper
• Preservation of DNA integrity in human and mouse leukemic cells induced to terminally differentiate by chemical agents.

  1981cited by this paper
• MATHEMATICAL ANALYSIS OF DNA DISTRIBUTIONS DERIVED FROM FLOW MICROFLUOROMETRY

  1974cited by this paper
• Heterotransplantation of human malignant tumors in "nude" thymusless mice. I. Breeding and maintenance of "nude" mice.

  1973cited by this paper
• Heterotransplantation of human malignant tumors in "nude" thymusless mice. I. Breeding and maintenance of "nude" mice.

  1973cited by this paper
• Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

  1972cited by this paper
• Treatment of malignant melanoma with camptothecin (NSC-100880).

  1972cited by this paper
• Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

  1972cited by this paper
• Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

  1970cited by this paper
• Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

  1966cited by this paper
• An Algorithm for Least-Squares Estimation of Nonlinear Parameters

  1963cited by this paper

• The Role of Long Noncoding RNAs in Cancer and Microbiota-derived Aryl Hydrocarbon Receptor Ligands

  2016cites this paper
• An overview of the molecular and cellular interactions of some bioactive compounds

  2015cites this paper
• Metabolic factors determining outcome in chemotherapy : studies with pazopanib

  2014cites this paper
• Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation.

  2014cites this paper
• In Vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel.

  2013cites this paper
• Methods other than Experimental Animals for Screening Antitumor Compounds

  2013cites this paper
• IN VIVO Screening Models of Anticancer Drugs

  2013cites this paper
• Camptothecins

  2012cites this paper
• Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin

  2007cites this paper
• Pharmacokinetic Modeling of Absorption Behavior of 9-Aminocamptothecin (9-AC) Released from Colon-specific HPMA Copolymer–9-AC Conjugate in Rats

  2007cites this paper
• Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia.

  2007cites this paper
• Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice.

  2007cites this paper
• Differential Susceptibility to Etoposide in Clones Derived from a Human Ovarian Cancer Cell Line

  2006cites this paper
• Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.

  2006cites this paper
• Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial

  2006cites this paper
• Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

  2005cites this paper
• Clinical Experience With 9-Aminocamptothecin

  2005cites this paper
• Mechanism of Action of Topoisomerase 1 Poisons

  2005cites this paper
• Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)

  2005cites this paper
• Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum.

  2005cites this paper
• A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.

  2005cites this paper
• Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.

  2005cites this paper
• Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.

  2005cites this paper
• Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.

  2004cites this paper
• Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.

  2003cites this paper
• Phase I I T rial o f I rinotecan i n P atients W ith M etastatic Epithelial O varian C ancer o r P eritoneal C ancer

  2003cites this paper
• Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

  2003cites this paper
• Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models.

  2003cites this paper
• Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC

  2003cites this paper
• Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.

  2002cites this paper
• 9-NITROCAMPTOTHECIN LIPOSOME AEROSOL: LACK OF SUBACUTE TOXICITY IN DOGS

  2002influential citation
• Current status and perspectives in the development of camptothecins.

  2002cites this paper
• CHAPTER 17 – RELEVANCE OF PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TO PHASE I TRIAL EXTRAPOLATION TECHNIQUES: RELEVANCE OF ANIMAL TOXICOLOGY

  2002cites this paper
• Why drugs fail: of mice and men revisited.

  2001cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients

  2001cites this paper
• 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies.

  2001cites this paper
• A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.

  2001cites this paper
• New Advances in Lung Cancer Chemotherapy: Topotecan and the Role of Topoisomerase I Inhibitors

  2001cites this paper
• Eradication of Minimal Disease in Severe Combined Immunodeficient Mice With Disseminated Daudi Lymphoma Using Chemotherapy and an Immunotoxin Cocktail

  2000cites this paper
• Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics.

  2000cites this paper
• Up-regulation of cyclin B1 and cdc2 expression during 9-nitrocamptothecin-induced regression of DU145 prostate tumor.

  2000cites this paper
• Telomerase activity, Myc and Bcl-2: possible indicators of effective therapy of prostate cancer with 9-nitrocamptothecin.

  2000cites this paper
• The Clinical Development of 9‐Aminocamptothecin

  2000cites this paper
• DNA topoisomerase I-targeting drugs as radiation sensitizers.

  1999cites this paper
• Water-insoluble camptothecin analogues as potential antiviral drugs.

  1999cites this paper
• Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

  1999cites this paper
• 9-Nitrocamptothecin Selectively Inhibits Human Immunodeficiency Virus Type 1 Replication in Freshly Infected Parental but Not 9-Nitrocamptothecin-Resistant U937 Monocytoid Cells

  1999cites this paper
• Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice

  1999cites this paper
• A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

  1999cites this paper
• Topoisomerase enzymes as drug targets.

  1999cites this paper
• In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).

  1999cites this paper
• Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro.

  1999cites this paper
• Water-Insoluble Camptothecin Analogues as Potential Antiviral Drugs

  1999cites this paper
• Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice.

  1999cites this paper
• A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer.

  1999cites this paper
• Altered Sensitivities to Anticancer and Differentiation Agents in Etoposide-Resistant Human Myeloid Leukemia U-937 Cells

  1998cites this paper
• Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

  1997influential citation
• Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.

  1997cites this paper
• Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.

  1997cites this paper
• Topoisomerase I Inhibitors

  1997cites this paper
• Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.

  1997cites this paper
• Camptothecin and Its Analogs

  1996cites this paper
• Monocytic differentiation and synthesis of proteins associated with apoptosis in human leukemia U‐937 cells acquiring resistance to Vincristine

  1996cites this paper
• Pharmacokinetics of Camptothecins Administered Orally a

  1996cites this paper
• Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL.

  1996cites this paper
• Camptothecin: A Promising Antiretroviral Drug.

  1996cites this paper
• Protocols for the Treatment of Human Tumor Xenografts with Camptothecins

  1996cites this paper
• Camptothecin and its analogs. An overview of their potential in cancer therapeutics.

  1996cites this paper
• Development of human leukemia U-937 cell sublines resistant to doxorubicin: induction of differentiation and altered sensitivities to topoisomerase-directed drugs.

  1995cites this paper
• Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.

  1995cites this paper
• Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.

  1995cites this paper
• Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples.

  1995cites this paper
• Induction of senescent cell-derived inhibitor of DNA synthesis gene, SDI1, in hepatoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin.

  1995cites this paper
• [Pharmacology of camptothecin and its derivatives].

  1995cites this paper
• The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies.

  1995cites this paper
• Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation

  1995cites this paper
• Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations.

  1995cites this paper
• The role of pH and serum albumin in the metabolic conversion of 9‐nitrocamptothecin to 9‐aminocamptothecin by human hematopoietic and other cells

  1995cites this paper
• Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action.

  1995cites this paper
• Antitumor effect of liposome‐incorporated camptothecin in human malignant xenografts

  1995cites this paper
• Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.

  1994cites this paper
• Xi Shu, A Promising Anti-tumor and Anti-viral Tree for the 21st Century

  1994cites this paper
• Conversion of 9‐nitro‐camptothecin to 9‐amino‐camptothecin by human blood cells in vitro

  1994cites this paper
• Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.

  1994cites this paper
• DNA topoisomerases: essential enzymes and lethal targets.

  1994cites this paper
• Development of resistance to 9‐nitro‐camptothecin by human leukemia U‐937 cells in vitro correlates with altered sensitivities to several anticancer drugs

  1994cites this paper
• Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin.

  1994cites this paper
• Partial characterization of human leukemia U‐937 cell sublines resistant to 9‐nitrocamptothecin P

  1994cites this paper
• Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts.

  1993cites this paper
• and in ovarian carcinomas . paraffin wax embedded normal tissues topoisomerase I in formalin fixed , Immunohistochemical detection of DNA

  year unknowncites this paper